Researchers examined provincial data for Shandong from 2014 through 2025, with 2020 treated as the reform-period reference point. The policy environment included Shandong’s vocational education innovation and development pilot zone, launched in 2020, amid a broader national restructuring of vocational education that began before the designated intervention year. The central interrupted time-series regression estimated whether the aggregate transition gap changed immediately around 2020 and whether its subsequent trajectory changed. The policy coefficient was −2.397, with p = 0.050, while the post-intervention trend coefficient was −0.053, with p = 0.864.

The study’s measure of educational disengagement was not a direct count of dropouts or an assessment of students’ psychological withdrawal from school. It was calculated as the difference between the number of junior-high graduates reported in Shandong and the combined number entering general senior secondary and secondary vocational schools, divided by the number of graduates. For example, 1.053 million graduates and 855,100 entrants produced a transition gap of 18.79% in 2019. That percentage can also reflect delayed enrollment, migration, cross-regional enrollment, alternative training pathways and differences in reporting conventions.

Across the full period, the measured gap rose from 17.77% in 2014 to a high of 23.74% in 2018, fell to 14.95% in 2020, and then remained near 18% through 2025. The average was 20.55% before the reform reference point and 17.81% after it. The regression therefore suggested a short-term level shift rather than a continuing structural decline. The study describes the reform as associated with improved access to the included upper-secondary pathways, but it does not establish that the policy itself produced the change or that students’ individual engagement improved.

Sensitivity analyses complicated the interpretation of the headline result. When 2018 was used as a placebo intervention year, the policy coefficient was negative but not statistically significant. When 2019 was substituted, however, the coefficient was −2.817 with p < 0.01, indicating that an intervention-like decline was already detectable before the formal 2020 reference point. A leave-one-year-out analysis retained negative coefficients in every tested specification, but significance changed: the estimate was −1.853 with p = 0.091 when 2018 was removed, −1.331 with p = 0.249 when 2020 was removed, and −2.941 with p = 0.017 when 2021 was removed.

The authors said the 2019 placebo result suggests that the transition gap may have begun declining during policy preparation, implementation or other earlier changes, making 2020 better understood as a period of institutional consolidation or intensification than as a clean policy shock. A Durbin–Watson statistic of 2.22 suggested that the baseline residuals did not exhibit substantial first-order positive or negative autocorrelation. Even so, the model’s 12 observations—six before and six after 2020—limited its statistical power and made estimates sensitive to individual years.

Juvenile justice involvement, measured as the annual number of juveniles involved in prosecution procedures, followed a different pattern. The count averaged 2,161 before 2020 and 3,651 afterward, an increase of 40.81%, while the educational transition gap declined by an average of 2.74 percentage points. Justice involvement peaked in 2022, two to three years after the gap reached its minimum in 2020. That timing was descriptively compatible with a possible delayed relationship, but it was not statistical evidence of one or proof of a particular lag.

Exploratory regression models found no significant association between aggregate disengagement and juvenile justice involvement either in the same year or with a one-year lag. The contemporaneous coefficient was 0.227 with p = 0.436, and the lagged coefficient was 0.139 with p = 0.667. The concurrent model had an R² of 0.682, compared with 0.663 for the lagged model, although those values describe the models as a whole rather than a significant education–justice relationship. The study therefore did not support its exploratory question at the provincial annual level.

Several limitations prevent the results from being read as evidence that educational reform reduces offending or that education and justice involvement are unrelated. Juvenile justice counts may reflect not only underlying behavior but also prosecutorial practices, reporting patterns and policies emphasizing reduced use of arrest, cautious prosecution and limited detention. Provincial annual data cannot observe school attachment, peer influence, family conditions, employment expectations or social integration, and they cannot identify which students entered the upper-secondary pathways or whether educational trajectories and justice involvement influenced each other. The findings also come from one province with distinctive policy and socioeconomic conditions, limiting generalization. More frequent and longer time series, comparison regions and individual- or school-level longitudinal data would be needed to determine whether any education–justice relationship emerges over longer periods.

Subject of Research: Exploratory analysis of upper-secondary education reform, educational transition gaps, and juvenile justice involvement in Shandong Province, China.

Article Title: Upper secondary education policy adjustment, educational disengagement and juvenile justice involvement: an interrupted time-series analysis in Shandong province, China, 2014–2025

Article References: Li, B. (2026). Upper secondary education policy adjustment, educational disengagement and juvenile justice involvement: an interrupted time-series analysis in Shandong province, China, 2014–2025. Frontiers in Education, 11, Article 1955861. https://doi.org/10.3389/feduc.2026.1955861

Image Credits: AI Generated

DOI: 10.3389/feduc.2026.1955861

Keywords: Shandong Province, upper-secondary education, vocational education reform, educational disengagement, interrupted time-series, juvenile justice, policy evaluation, China, Upper, secondary, education, policy

Participants had a median age of 80.7 years, with an interquartile range of 73.8 to 86.2 years, and 61.4% were female. From 2010 through 2022, the researchers measured quarterly prescribing rates for typical opioids, tramadol and buprenorphine, together with the gabapentinoids gabapentin and pregabalin. Using an interrupted time-series design, the researchers estimated whether the level and slope of prescribing changed after the CDC released its guideline in March 2016.

Level estimates represented immediate changes in quarterly prescribing rates, while slope estimates captured changes in those rates over time. As an observational analysis, the study assessed an association with the guideline release rather than establishing that the guideline caused the observed prescribing patterns. The results therefore do not support causal attribution of the measured changes to the guideline itself.

Typical opioid prescribing declined by 26.5% over the full study period, but the model did not identify that decline as guideline-related. The estimated change in quarterly trend was 0.09 percentage points, with a 95% confidence interval of −0.1 to 0.3 percentage points, while the estimated immediate level change was −1.5 percentage points, with a 95% confidence interval of −4.1 to 1.0 percentage points. The study thus distinguished the overall decline observed from 2010 to 2022 from the changes statistically associated with the intervention period.

Tramadol showed a different post-guideline pattern. Guideline release was associated with a 27.1% decrease in tramadol prescribing, expressed in the model as an immediate level change of −1.8 percentage points and a trend change of −0.2 percentage points per quarter. Both estimates had 95% confidence intervals that excluded zero: −3.1 to −0.6 percentage points for the level change and −0.3 to −0.1 percentage points for the trend change.

These findings support a selective association between the guideline period and lower tramadol prescribing, rather than a general reduction across opioid categories. Gabapentinoid prescribing, meanwhile, increased from 9.5% to 11.5% during the study period, with no modeled change in trend after the guideline release. The estimated trend change was 0.0 percentage points per quarter, with a 95% confidence interval of −0.01 to 0.02 percentage points.

Buprenorphine prescribing remained near zero throughout. Because the study measured medication use rather than pain relief, adverse effects or symptom control, it could not determine whether the observed analgesic shifts benefited patients or reduced medication-related harm. The population also has heightened exposure to the competing concerns identified in the study’s rationale: the risk of pain undertreatment and the risk of adverse medication effects.

However, the research did not directly compare those outcomes, and its scope was limited to community-dwelling older adults with dementia represented in a national survey. The findings therefore offer no direct evidence about pain treatment or safety outcomes. The authors concluded that the results show analgesic selection shifts after the guideline release, that the clinical impact of those shifts remains unknown, and that more nuanced, evidence-based analgesic prescribing guidance is needed for older adults with dementia.

Subject of Research: Changes in opioid and gabapentinoid prescribing among community-dwelling older adults with dementia after the 2016 CDC opioid prescribing guideline

Article Title: Opioid and Gabapentinoid Prescribing in Older Adults with Dementia Before and After the 2016 CDC Opioid Prescribing Guideline

Article References: Veschio, T., McKendrick, K., Li, L., Harrison, K., Hunt, L. J., Muench, U., Smith, C. B., Aldridge, M., Sean Morrison, R., & Rodin, R. (2026). Opioid and Gabapentinoid Prescribing in Older Adults with Dementia Before and After the 2016 CDC Opioid Prescribing Guideline. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10932-3

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10932-3

Keywords: dementia, opioid prescribing, CDC guideline, gabapentinoids, tramadol, older adults, Medicare claims, interrupted time series, pain treatment, Opioid, Gabapentinoid, Prescribing

The scale of the problem the region set out to solve is familiar to health systems everywhere. Emergency department overcrowding is driven in large part by high volumes of low-complexity cases, patients with conditions that need prompt attention but not the full apparatus of a hospital emergency service. In 2023, Emilia-Romagna launched a network of community-based Urgent Care Centers, or UCCs, designed to intercept these visits before they reached hospital doors. By April 2025, 43 such centers were operating across the region, and the new study set out to measure what happened to emergency department traffic as they came online.

The research team, led by Daniela Fortuna and Dario Tedesco of the Emilia-Romagna regional health directorate along with collaborators from the universities of Bologna and Parma, took advantage of a natural experiment. Because the centers opened at staggered times across different districts, the investigators could apply an interrupted time-series design, using segmented regression models to compare observed daily low-acuity emergency visit volumes against the trajectory that would have been expected based on pre-opening trends, while adjusting for annual and weekly seasonality. The data came from routinely collected regional health databases spanning January 2022 to April 2025.

The headline finding is striking. On average, after the opening of the first urgent care center in a district, daily low-acuity emergency department visits ran 13.5 percent lower than expected, with a confidence interval running from minus 13.9 to minus 13.0 percent. And the effect grew as the regional network expanded. In the later periods of the study, the shortfall deepened to 22.5 percent and then 23.6 percent below expected levels, suggesting that the centers became more effective at diverting appropriate patients as coverage and public familiarity spread.

But the most consequential result is not the average. It is the enormous spread across organizational models. Urgent care centers that shared a pre-triage pathway with the emergency department, so that patients arriving at the hospital could be redirected on the spot to the adjacent urgent care service, cut low-acuity emergency visits by 42.2 percent. Community-based centers located far from hospitals, without that shared access point, achieved only a modest 9.5 percent reduction. And centers physically adjacent to hospitals but lacking the shared pre-triage arrangement showed essentially no reduction at all, at minus 0.7 percent, a figure statistically indistinguishable from zero.

That pattern carries a clear message for planners: physical proximity to a hospital is not enough, and neither is simply adding urgent care capacity somewhere in the community. What appears to matter is integration, the deliberate engineering of a single front door through which patients with urgent but low-complexity needs are sorted and routed. A shared pre-triage model means the patient who shows up at the emergency department with a sprained ankle or a fever does not need to know in advance where to go; the system redirects them. Community sites, by contrast, depend on patients self-selecting, which the data suggest happens far less reliably.

The study’s multilevel logistic regression analysis reinforced that point from the patient side. The strongest predictor of whether a resident used an urgent care center rather than an emergency department was simply whether a center existed in the municipality of residence, which raised the odds of urgent care use roughly sevenfold. Convenience and geographic access, in other words, shape urgent care behavior powerfully, but they operate most effectively when combined with system-level routing rather than left to individual navigation.

The case mix comparison between urgent care centers and low-acuity emergency visits adds further texture. The centers, nearly half of which were embedded in Community Health Centers and roughly 37 percent located within hospitals, with 46.5 percent offering round-the-clock coverage, were handling precisely the kind of urgent-but-not-emergent presentations that clog emergency departments. That alignment between what the centers treat and what the emergency departments were shedding is what makes the volume shifts interpretable as diversion rather than mere displacement.

The authors are appropriately careful about causal claims. Because no contemporaneous untreated comparator region was available, they caution that the observed differences should not be interpreted as effects attributable solely to the urgent care implementation. Secular trends, concurrent policy changes, or shifts in patient behavior could in principle contribute to the pattern. Still, the dose-response relationship, with effects strengthening as the network expanded and concentrating where integration was deepest, is difficult to explain without invoking the centers themselves.

For health systems grappling with emergency department overcrowding, the Emilia-Romagna experience offers a concrete design lesson wrapped in rigorous time-series evidence. Urgent care centers are not interchangeable widgets; their impact on emergency department load depends on whether they are stitched into a shared access and pre-triage pathway or left as isolated alternatives. As regions elsewhere consider similar investments, the Italian data suggest that the architecture of the network, not just the number of centers, will determine whether the emergency department finally gets the relief it needs.

Subject of Research: Effect of urgent care center integration into primary care networks on low-acuity emergency department utilization

Article Title: Integrating urgent care centers into primary care networks to reduce emergency department overcrowding: a real-world implementation and evaluation

Article References: Fortuna, D., Golinelli, D., Caranci, N., Grilli, R., Donatini, A., Alberani, M., Marinelli, S., Berti, E., Tedesco, D., Emilia-Romagna UCC Working Group, Barbagallo, V., Bartoli, S., Casoni, F., Cisbani, L., Clo, M., Fabbri, E., Gentili, A., Lama, B., Marino, M., … Camplone, I. (2026). Integrating urgent care centers into primary care networks to reduce emergency department overcrowding: a real-world implementation and evaluation. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15566-z

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15566-z

Keywords: emergency department overcrowding, urgent care centers, primary care, interrupted time series, health services research, pre-triage, Emilia-Romagna, low-acuity visits, health policy, community health centers, patient diversion, Italy

The answer, published in BMC Health Services Research, is a qualified yes, with important caveats about what happens after a positive test. Benjamin Sloan, Annie N. Cowell, Christina Schultz, Amy Sitapati, Marie-Reine Lauer, Ryan Moran and colleagues implemented an EHR-based algorithm to identify patients at risk of latent tuberculosis infection, or LTBI, using discrete data elements that trigger an Epic Health Maintenance topic flag. The Health Maintenance topic is a structured, patient-specific EHR feature used to document and track completion of recommended preventive care. In other words, rather than relying on clinicians to remember which patients need TB risk assessments, the system itself flags the recommendation, embedding it in the same preventive-care machinery that reminds providers about vaccines and cancer screening.

The technical architecture matters because LTBI screening is fundamentally a data problem. Risk factors for LTBI, such as birth or travel in high-prevalence countries, known exposure to active TB, immunosuppression, and homelessness or incarceration, are typically recorded in the chart as structured fields: demographic entries, problem-list items, social history elements. The UC San Diego team built staff- and clinician-centered workflows on top of these discrete data elements so that risk assessment determination could be completed during routine encounters. The algorithm does not diagnose LTBI; it identifies candidates for risk assessment and, where risk factors are confirmed, for Interferon-Gamma Release Assay testing, the modern blood-based diagnostic that has largely replaced the older tuberculin skin test in primary care.

To evaluate whether the algorithm actually changed behavior, the researchers conducted a retrospective quasi-experimental study tracking monthly QuantiFERON, or QFT, orders before and after the Health Maintenance topic went live in June 2025. The statistical approach was interrupted time series segmented regression over 47 months, from January 2022 through November 2025, a method that models the baseline trend, the immediate level change at intervention, and the post-intervention slope separately. Because seasonal patterns can distort such comparisons, the team also ran a seasonally matched sensitivity analysis comparing June through November 2025 against the same months in 2022 through 2024.

The results were striking. The interrupted time series analysis demonstrated a significant immediate increase of 547.42 additional QFT orders at implementation, with a p-value below 0.001. That is, in the month the algorithm switched on, testing volume jumped by roughly 550 orders, an effect far too large to attribute to chance. The post-intervention slope subsequently declined by 103.17 orders per month, p = 0.006, suggesting the initial surge partially receded as the backlog of flagged patients was worked through. The seasonally matched comparison confirmed significantly higher mean monthly QFT orders in June through November 2025, at 2055.17, versus 1795.33 in the same months of 2022 through 2024, a mean difference of 259.83 orders with a 95 percent confidence interval of 1.19 to 518.48 and p = 0.049. The effect size, Cohen’s d of 1.35, indicates a large difference by conventional statistical standards.

Over five months of post-implementation monitoring, more than 13,000 patients were identified by the algorithm, and QFT positivity rates ran at 10 percent. That positivity rate is notable: it suggests the algorithm is not merely casting a wide net but flagging patients whose risk profiles genuinely correlate with infection. In a low-prevalence setting, indiscriminate testing would yield mostly negative results; a 10 percent yield among flagged patients indicates meaningful enrichment, the kind of signal that makes population screening economically and clinically defensible.

But the study’s most sobering findings lie downstream of the blood draw. The researchers conducted a structured chart review of QFT-positive patients to evaluate care cascade outcomes, including chest radiography completion and LTBI treatment initiation. Among 103 QFT-positive patients, 75, or 72.8 percent, had chest radiography ordered. Of those, only 50, or 66.7 percent, had a documented imaging result available. And among patients with normal imaging, the standard prerequisite for ruling out active disease before starting preventive therapy, only 23.3 percent initiated LTBI treatment. The attrition is severe at every step: roughly one in four positive patients never got a chest image ordered, a third of those ordered never produced a documented result, and fewer than one in four eligible patients actually started the antibiotics that would eliminate their infection risk.

This cascade gap is where the study’s implications become sharpest for TB elimination strategy. Latent tuberculosis infection is asymptomatic, so treatment offers no immediate benefit the patient can feel; it requires months of medication, sometimes with side effects, for a benefit that is entirely probabilistic and deferred. Public health frameworks have long recognized that screening without treatment completion does little to reduce future TB cases, since the bacterium remains in the population. The UC San Diego findings highlight that the EHR algorithm succeeded at the front end, converting a mandate into testing volume, but that diagnostic follow-up and treatment initiation remain the persistent barriers. The authors point to low primary-care encounter ordering rates and incomplete follow-up of positive results as key gaps, framing them as opportunities for workflow optimization to advance AB 2132 compliance and regional TB elimination goals.

The technical lesson for health informatics is that EHR-based screening algorithms can be built quickly and can produce measurable population-level effects, but they function best as part of a closed loop rather than a one-way flag. A Health Maintenance topic that identifies 13,000 at-risk patients and drives a 10 percent positivity rate is a triumph of data engineering; a system in which only 23 percent of eligible positive patients start treatment is a triumph of identification without completion. Closing that loop will likely require the same discrete-data discipline applied downstream: automated tracking of chest radiography orders and results, automated outreach to patients with normal imaging, and treatment initiation prompts embedded in the same preventive-care machinery that drove the testing surge. The UC San Diego team has demonstrated that the front door of TB elimination can be opened with code. The harder work, as their own cascade data show, is what happens once patients walk through it.

Subject of Research: Health Services Research

Article Title: EHR-based algorithm for latent tuberculosis infection screening in primary care: early implementation under California AB 2132

Article References: Sloan, B., Cowell, A. N., Schultz, C., Sitapati, A., Lauer, M.-R., & Moran, R. (2026). EHR-based algorithm for latent tuberculosis infection screening in primary care: early implementation under California AB 2132. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15658-w

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15658-w

Keywords: latent tuberculosis infection, EHR algorithm, AB 2132, primary care, San Diego, QuantiFERON, interrupted time series, care cascade, health informatics, public health policy, EHR-based, algorithm

The Oahu experience offers a rare window into how a prehospital triage policy behaves when the usual confounders of real-world stroke systems are largely removed. In most metropolitan regions, patients with suspected large vessel occlusion can be routed to any of several thrombectomy-capable hospitals, each with its own workflows, staffing patterns, and activation criteria. That heterogeneity makes it difficult to attribute changes in treatment times to the bypass policy itself rather than to differences between receiving centers. On Oahu, by contrast, a single comprehensive stroke center receives all endovascular candidates, decisions about mechanical thrombectomy are made by one unified team of stroke neurologists and neurointerventionalists, and a single EMS agency handles prehospital transport for the entire island of roughly one million residents within 597 square miles. This closed-loop structure means that any shift in onset-to-door time observed after August 1, 2019—the date the bypass protocol took effect island-wide—can be interpreted with considerably more confidence than in open systems where patient migration between competing centers muddies the analysis.

The mechanics of the protocol deserve attention because they illustrate how prehospital stroke science is translated into dispatch-level practice. Under the Oahu scheme, EMS providers administer the Cincinnati Stroke Triage Assessment Tool, a brief field examination designed to discriminate cortical large vessel occlusions from smaller infarcts that do not benefit from thrombectomy. Patients scoring two or higher are classified as bypass-positive and transported directly past the nearest community hospital to the comprehensive stroke center, even when that nearest hospital would otherwise have been only minutes away. Before the policy change, standard EMS doctrine directed transport to the closest emergency department regardless of stroke severity, with exceptions reserved for major trauma or provider discretion. The consequence of the old doctrine was predictable: a patient with a disabling LVO would arrive at a community hospital, undergo initial evaluation and imaging, be recognized as needing endovascular therapy, and then require a second ambulance transfer to the comprehensive stroke center—consuming the very hours during which penumbral brain tissue remains salvageable.

The five-fold decline in interfacility transfers for endovascular therapy, from 55.9 percent of cases before implementation to 11.6 percent afterward, is arguably the most operationally meaningful finding in the study. Interfacility transfer is the single largest source of avoidable delay in stroke systems of care, because it compounds two ambulance trips, two emergency department evaluations, two imaging workflows, and two handoffs into a single treatment timeline. National quality registries have repeatedly shown that patients who require a drip-and-ship transfer to reach a thrombectomy-capable center lose substantial time compared with those who arrive directly. By collapsing that two-step journey into one, the Oahu protocol eliminated the dominant structural delay in the island’s treatment chain, and the 66-minute sustained reduction in onset-to-door time measured by the interrupted time series analysis is the direct arithmetic consequence of that collapse.

The interrupted time series design strengthens the causal interpretation in ways that a simple before-and-after comparison cannot. By grouping treatment times into quarterly averages and modeling both the change in level and any change in slope after implementation, the analysis distinguishes an abrupt policy effect from a gradual secular trend. The Durbin-Watson assessment for autocorrelation further guards against the possibility that the observed drop merely reflects a pre-existing downward drift in treatment times that happened to coincide with the protocol launch. The finding of a sustained level shift with no change in temporal trend indicates that the bypass produced a discrete, durable improvement rather than accelerating an ongoing improvement that would have occurred anyway.

Equally important is what did not get worse. A persistent concern with bypass protocols is that routing the sickest patients past community hospitals might delay thrombolysis for patients who turn out not to have an LVO, or who would have benefited from rapid intravenous thrombolytic administration at the nearest facility. The Oahu data showed no significant change in onset-to-thrombolytic time after implementation, which suggests that the field screening tool and the routing logic did not systematically penalize patients who still needed intravenous reperfusion therapy. This finding aligns with the broader literature on LVO scales, which generally accept a modest trade-off in thrombolysis timing in exchange for large gains in thrombectomy timing, but it is reassuring to see that trade-off was not required on Oahu.

The relationship between time and outcome that emerged from the multivariate modeling reinforces why these minutes matter. Every additional 30 minutes of delay from symptom onset to successful reperfusion increased the odds of a worse 90-day modified Rankin Scale score by six percent, an effect consistent in direction and magnitude with the time-to-treatment gradients reported in randomized thrombectomy trials and pooled patient-level meta-analyses. The biology underlying this gradient is well characterized: each minute of persistent arterial occlusion converts salvageable penumbral tissue into irreversibly infarcted core, so the functional benefit of reperfusion decays continuously with time. A 41-minute reduction in onset-to-reperfusion time, even one that fell short of conventional statistical significance in this cohort, would therefore be expected to translate into a modest but real shift in the distribution of disability—provided the cohort is large enough and the time savings reach the patients who stand to gain the most.

That last caveat is where the Oahu results become most instructive about the limits of systems interventions. Despite the substantial and sustained reduction in treatment times, the post-bypass era was not associated with a statistically significant improvement in good 90-day outcomes, defined as modified Rankin Scale scores of zero to two, and the adjusted odds ratios for both good outcomes and the ordinal shift in disability hovered near unity. There was, however, a suggestive trend toward more excellent outcomes—scores of zero or one—which rose from 23.5 percent to 34.5 percent in unadjusted comparison and retained a positive but non-significant adjusted association. The most plausible reading is that the study was underpowered to detect the modest outcome benefit that a 41-minute time saving would be expected to produce. With 102 patients in the pre-bypass era and 249 in the post-bypass era, and with functional outcome influenced by many factors beyond timing—age, baseline stroke severity, clot location, reperfusion success, and symptomatic hemorrhage among them—the signal from a time saving of this size may simply be diluted below the threshold of detectability.

Several other factors may also have blunted the observable outcome benefit. The institutional criteria for mechanical thrombectomy during the study period required a baseline modified Rankin Scale of zero to two, an NIH Stroke Scale score of at least six, and an ASPECTS score between six and ten, which restricts the treated population to patients with moderate to severe anterior circulation strokes and reasonable pretreatment function. Patients at the milder end of the spectrum, who might have gained the most from faster reperfusion in absolute terms of preserved independence, were not eligible for the procedure at all. Additionally, the bypass protocol changed not only where patients went but who arrived at the comprehensive stroke center; if the post-bypass cohort included more severe or more bypass-positive patients by design, case-mix shifts could offset some of the timing gains in the adjusted models. The investigators addressed this by adjusting for age, baseline NIHSS, clot location, reperfusion status, and symptomatic hemorrhage, but residual confounding in a retrospective design is inevitable.

The comparison with RACECAT and TRIAGE-STROKE, the two randomized trials of prehospital bypass strategies, adds an important layer of interpretation. Both trials confirmed that direct transport to thrombectomy-capable centers shortens onset-to-puncture times, yet neither demonstrated improved functional outcomes, mirroring the Oahu pattern of time savings without proven outcome benefit. The convergence of these findings across a randomized European trial, a randomized Catalan trial, and a natural experiment in a closed island system suggests that the time-outcome relationship, while real at the individual patient level, is difficult to demonstrate at the system level when the time savings are measured in tens of minutes rather than hours. It also raises the possibility that the benefit of bypass is heterogeneous: patients with the longest prehospital delays, the largest salvageable penumbras, or the most accessible occlusions may benefit substantially, while the cohort average dilutes that benefit.

For stroke systems planners, the practical lessons are nonetheless concrete. First, a simple, validated field tool administered by a single EMS agency can reliably redirect LVO candidates and produce large, durable reductions in door time without harming thrombolysis delivery. Second, the magnitude of benefit from bypass depends heavily on the baseline system: in regions where interfacility transfer rates are as high as the 55.9 percent seen on Oahu before implementation, the headroom for improvement is enormous, whereas systems that already route most patients directly may see smaller gains. Third, geography matters. Oahu’s compact, single-center catchment meant that bypass added relatively little transport time for most patients; in sprawling regions where the nearest thrombectomy-capable center is far away, the calculus of bypass versus nearest-hospital-first becomes more complex and may favor drip-and-ship for some patients. Finally, the Oahu experience underscores that process metrics, while necessary, are not sufficient—demonstrating that a systems intervention improves the lives of stroke patients ultimately requires either larger cohorts, longer follow-up, or composite endpoints sensitive enough to capture the modest population-level shifts that faster reperfusion can deliver.

Subject of Research: Prehospital large vessel occlusion bypass protocol and its effect on endovascular stroke treatment times and outcomes

Article Title: Reducing onset-to-door times through the implementation of a prehospital large vessel occlusion bypass protocol: the Oahu experience

Article References: Sun, C.-H., Chun, I., Nakagawa, K., Brown, S., Tsappidi, S., Hui, F., Zhang, Y., Salem, R., Zhang, G., Galanis, D., & Koenig, M. (2026). Reducing onset-to-door times through the implementation of a prehospital large vessel occlusion bypass protocol: the Oahu experience. Frontiers in Stroke, 5, Article 1903852. https://doi.org/10.3389/fstro.2026.1903852

Image Credits: AI Generated

DOI: 10.3389/fstro.2026.1903852

Keywords: stroke, large vessel occlusion, endovascular thrombectomy, EMS bypass protocol, prehospital triage, onset-to-door time, reperfusion, comprehensive stroke center, Oahu, interrupted time series, modified Rankin Scale, mobile stroke units

Respiratory syncytial virus, or RSV, is the leading cause of bronchiolitis, a viral infection of the small airways that sends hundreds of thousands of infants to hospitals across Europe each winter. For decades, pediatricians had little to offer beyond supportive care, since a previous antibody product, palivizumab, was reserved for high-risk infants because of its high cost and the need for monthly injections. Nirsevimab changed that calculus. A single dose provides protection lasting at least five months, covering an entire RSV season, and clinical trials demonstrated strong efficacy against medically attended lower respiratory tract infection in healthy term and preterm infants alike.

When nirsevimab finally became available in Europe in late 2023, national and regional health authorities adopted it at different speeds and with different strategies. Some countries launched universal immunization programs targeting all infants entering their first RSV season, while others restricted initial campaigns to infants born during or just before the season, and a few had no program at all during the study window. This patchwork of implementation created an unintended natural experiment, and a large consortium of European pediatric emergency researchers seized the opportunity to measure what happened.

The research team, led by Léa Lenglart and Naim Ouldali with the EPISODES Study Group, assembled routinely collected data from 27 pediatric emergency departments spanning 12 European countries, covering the period from January 2018 through March 2024. They included every case of bronchiolitis diagnosed in infants younger than 12 months, yielding a total of 107,088 episodes. Regions were classified as intervention or control depending on whether nirsevimab had been implemented, and immunization coverage figures were drawn from official regional reports. Urinary tract infections in the same age group served as a control outcome, a standard technique to detect whether observed changes reflect a real intervention effect or some unrelated shift in emergency department attendance.

The analytical approach was a controlled interrupted time-series design, a method well suited to evaluating population-level interventions introduced at a known point in time. The models accounted for underlying seasonality and pre-existing temporal trends, allowing the researchers to estimate how much of the change in monthly bronchiolitis cases during the intervention period, from October 2023 through March 2024, could be attributed to the antibody program rather than to the ordinary rhythm of winter epidemics. Estimates were stratified by age group, separating infants aged 0 to 3 months, who face the highest risk of severe disease, from those aged 3 to 12 months.

The results were striking in both their magnitude and their heterogeneity. Reductions in bronchiolitis visits ranged from essentially no change, with one estimate of plus 0.6 percent, to a remarkable 61 percent decline, with a confidence interval stretching from minus 67.8 to minus 35.2 percent. Infants in the youngest age band generally showed the largest reductions, consistent with the biology of RSV, since the highest rates of hospitalization and intensive care admission occur in the first months of life. Meanwhile, bronchiolitis trends in control regions without nirsevimab programs remained stable, and urinary tract infection visits showed no comparable decline, strengthening the argument that the observed reductions were tied to the immunization campaigns rather than a general drop in emergency presentations.

Perhaps the most consequential finding was the strength of the statistical relationship between coverage and benefit. Across regions and age groups, the correlation between nirsevimab coverage and the percentage reduction in bronchiolitis visits was negative and pronounced, with a correlation coefficient of minus 0.86 and a p-value of 0.001. In practical terms, regions that immunized a larger share of their infant population saw proportionally larger drops in emergency department visits. The relationship held across both age strata, suggesting that the antibody’s protective effect translated into population benefit wherever it reached enough infants, whether they were immunized at birth during the season or through catch-up campaigns targeting older babies.

Why did coverage differ so much across Europe? The study points to implementation choices as the decisive variable. Countries and regions that embedded nirsevimab into routine newborn care, offering the dose in maternity wards before discharge, achieved far higher uptake than those relying on later appointments or opportunistic vaccination during other visits. Administrative hurdles, supply constraints, differences in eligibility criteria, and varying levels of parental and clinician acceptance all likely contributed. The authors emphasize that the antibody’s intrinsic efficacy, already demonstrated in randomized trials, was never in question; what varied was the fraction of the infant population that actually received it in time to be protected when the virus arrived.

The researchers are careful about the limits of their design. As an ecological study, it examines populations rather than individuals, so causality cannot be definitively inferred. Unmeasured regional differences, such as changes in testing practices, health-seeking behavior, viral circulation intensity, or concurrent public health measures, may have contributed to some of the observed variability. The interrupted time-series models adjust for seasonality and trend, and the stability of control outcomes argues against simple artifacts, but the authors acknowledge that residual confounding remains possible. Still, the consistency of the findings across 27 departments, multiple countries, and two age groups, together with the tight coverage-response relationship, makes a compelling case that immunization coverage was a key driver of the reductions.

The implications for health policy are immediate. RSV prevention has entered a new era, with nirsevimab programs now expanding and maternal RSV vaccines adding another layer of protection for newborns. This study demonstrates that the public health return on these interventions depends not only on the biology of the product but on the machinery of delivery. Regions that achieved high coverage among both season-born and out-of-season infants reaped reductions in bronchiolitis visits of a scale rarely seen for a respiratory disease, easing pressure on emergency services during the busiest weeks of the winter. For health authorities weighing how to structure their own programs, the European experience of 2023–2024 offers a clear lesson: the fastest, broadest, and earliest possible reach into the infant population is what converts a highly effective antibody into a visible decline in disease. As nirsevimab programs mature and additional seasons of data accumulate, researchers will be watching to see whether the coverage-response relationship holds, whether protection extends to severe outcomes such as intensive care admission, and whether the substantial regional variability in implementation narrows as systems learn from one another.

Subject of Research: Association between nirsevimab immunization coverage and reductions in infant bronchiolitis emergency department visits across 12 European countries

Article Title: Association between nirsevimab coverage and pediatric emergency department visits for bronchiolitis in 12 European countries: An interrupted time-series analysis

Article References: Lenglart, L., Titomanlio, L., Alberti, I., Almeida, L., Aupiais, C., Akyüz Özkan, E., Barrett, M., Basmaci, R., Birbilen, A., Borensztajn, D., Schönenberger, C. B., Bressan, S., Buonsenso, D., Campos, T., Castanhinha, S., Chiaretti, A., Claret, G., De Zan, F., Durnin, S., … the EPISODES Study Group (2026). Association between nirsevimab coverage and pediatric emergency department visits for bronchiolitis in 12 European countries: An interrupted time-series analysis. PLOS Medicine, 23(9), e1005223. https://doi.org/10.1371/journal.pmed.1005223

Image Credits: AI Generated

DOI: 10.1371/journal.pmed.1005223

Keywords: nirsevimab, RSV, bronchiolitis, infants, pediatric emergency departments, immunization coverage, interrupted time-series, Europe, PLOS Medicine, monoclonal antibody, respiratory syncytial virus, public health

The research team, led by Alejandro Macchia and Daniel Ferrante of Argentina’s Ministry of Health together with Gianni Tognoni of the Permanent Peoples’ Tribunal in Rome, assembled a balanced panel of 9,910 specific commercial presentations spanning June 2021 to March 2026. That panel yielded 584,690 presentation-month observations, an unusually rich dataset for a question that is usually addressed through surveys or anecdote. Rather than asking people whether they had skipped doses, the researchers measured affordability directly from prices: they calculated how much of a single minimum pension would be required to purchase thirty defined daily doses of medicines in eight major outpatient therapeutic families, from antihypertensives to antipsychotics.

The methodological backbone of the study is an interrupted time-series design, a technique that treats a policy change as a natural experiment by comparing trends before and after a known intervention date. Because the panel included fixed effects for each specific commercial presentation, the models could control for the fact that different products have different baseline prices and different trajectories. The team divided the observation window into three phases: a pre-shock period, an acute-shock period immediately following December 2023, and a post-shock period through March 2026. This structure allowed them to separate the abrupt discontinuity caused by the shock from the slower drift in affordability that was already underway.

That pre-existing drift matters. Between June 2021 and March 2026, the median cumulative price increase across the medicines studied was 1,951 percent. Cumulative inflation over the same period reached 2,191 percent, while the minimum pension rose by only 1,502 percent. Those three numbers tell the story in miniature: drug prices roughly kept pace with the general price level, but the income of the most vulnerable pensioners lagged far behind. In other words, even before the December 2023 shock, affordability was deteriorating across all eight therapeutic families, a slow erosion that the shock then dramatically accelerated.

The acute phase of the shock produced a sharp fall in purchasing power. Argentina’s December 2023 policy package included a steep devaluation of the peso, the removal of price controls and subsidies, and aggressive fiscal adjustment, all of which fed into a burst of inflation that outpaced the periodic adjustments to the minimum pension. For a retiree depending on that pension, the arithmetic is unforgiving: when prices jump faster than income, the quantity of medicine a monthly budget can buy shrinks. The interrupted time-series models captured this as a sudden break in the affordability series, superimposed on the already negative pre-shock trend.

What is most striking is what happened afterward. By March 2026, long after the initial turbulence, the affordability burden remained above the pre-shock average in every one of the eight therapeutic families examined. The excess burden was not evenly distributed. Antiparkinsonian medicines showed the largest persistent gap, with affordability 31.5 percent worse than the pre-shock average, a difference the authors report with a 95 percent confidence interval of 14.8 to 50.5 percent. Antithrombotic medicines, which prevent the clots that cause strokes and heart attacks, carried a 22.8 percent excess burden (95 percent CI, 15.9 to 30.0), and antipsychotic medicines a 20.2 percent excess burden (95 percent CI, 14.5 to 26.2).

The therapeutic profile of the hardest-hit categories is itself a warning. Parkinson’s disease, cardiovascular disease and severe mental illness are precisely the conditions in which uninterrupted treatment is critical and in which interruption carries immediate clinical consequences. A retiree who cannot afford an antithrombotic faces a quantifiable rise in stroke risk; a patient with psychosis who runs out of medication risks relapse and hospitalization. The study did not measure whether patients actually skipped doses, but the affordability metric it does measure, the fraction of a minimum pension consumed by a standard monthly supply, is a well-established proxy for the financial barrier to adherence, and it moved decisively in the wrong direction.

The authors frame Argentina as a model case for studying medication-affordability vulnerability under macroeconomic shock, and the framing has implications well beyond one country. In high-inflation settings, they note, formal medicine availability can coexist with declining affordability: pharmacies may be fully stocked, yet the drugs remain out of reach for those on fixed incomes. This distinction challenges a common assumption in pharmaceutical policy that supply-side indicators, such as stockouts and registration status, are sufficient measures of access. Argentina’s experience shows that a country can maintain nominal availability while the effective access of its poorest citizens quietly collapses.

The policy prescription that emerges from the analysis is the need for countercyclical mechanisms that protect the purchasing power of vulnerable populations during macroeconomic adjustment. Pension indexation that lags inflation, as Argentina’s did over this period, effectively transfers the cost of stabilization onto pensioners, and the medicine price data reveal exactly where that transfer lands. The authors argue that pharmaceutical policy should not be treated as a passive bystander to macroeconomic reform; targeted subsidies, differential price regulation for essential chronic medicines, or automatic affordability-linked adjustments could buffer the shock for those least able to absorb it. Without such mechanisms, they suggest, stabilization programs will continue to generate hidden health costs that surface later as untreated disease.

The study has limitations worth noting, and the authors are transparent about its scope. It used aggregated, publicly available data rather than individual patient records, so it measures affordability rather than actual consumption, and it did not require ethics approval because no human subjects were involved. The analysis received no specific funding from any public, commercial or not-for-profit agency, and the authors declare no competing interests. Yet the scale and granularity of the panel, nearly 585,000 observations across eight therapeutic families and almost five years, give the findings a robustness that few affordability studies achieve. As other economies confront their own inflationary shocks and adjustment programs, the Argentine case stands as a quantitative demonstration that the price of macroeconomic discipline is not always counted in currency markets. Sometimes it is counted in monthly pension fractions, one prescription at a time, among people who can least afford to pay.

Subject of Research: The impact of shock economic policies on the affordability of essential medicines for older adults in Argentina

Article Title: Effects of shock economic policies on access to essential medicines among older adults in Argentina: an interrupted time-series analysis (2021–2026)

Article References: Macchia, A., Tognoni, G., & Ferrante, D. (2026). Effects of shock economic policies on access to essential medicines among older adults in Argentina: an interrupted time-series analysis (2021–2026). International Journal for Equity in Health. https://doi.org/10.1186/s12939-026-03023-6

Image Credits: AI Generated

DOI: 10.1186/s12939-026-03023-6

Keywords: Argentina, essential medicines, economic shock, drug affordability, older adults, minimum pension, inflation, interrupted time series, pharmaceutical policy, health equity, pharmacoeconomics, access to medicines

The research team, led by Joon Young Song of Korea University College of Medicine together with colleagues from Seoul National University, IQVIA and Merck, set out to quantify a gap that has long frustrated epidemiologists in the region. Reliable information on how pneumococcal disease affects adults in South Korea, and on whether vaccination programs have altered that picture, has been limited. To fill it, the investigators turned to one of the most powerful tools available in modern health research: a nationwide claims database covering virtually the entire population. They identified every hospitalization episode among adults aged 18 and older coded as invasive pneumococcal disease or pneumonia between 1 January 2010 and 31 December 2019, using the Korean version of the International Classification of Diseases to flag cases.

The study window was deliberately split around the 2014 vaccine rollout. Hospitalizations from 2010 to 2013 served as the pre-vaccination baseline, while those from 2015 to 2019 captured the post-introduction era, with the transition year excluded to allow the program to take hold. Rather than simply comparing average rates between the two periods, the researchers applied interrupted time series analysis, a statistical technique that separates an abrupt change in the level of a trend from a gradual change in its slope. Results were expressed as incidence rate ratios, with a value above 1 signaling an increase and a confidence interval crossing 1 indicating statistical uncertainty.

Over the full ten years, the database yielded 1,682 hospitalization episodes of invasive pneumococcal disease and 8,635 episodes of pneumonia among adults. Those raw counts translate into overall incidence rates of 0.4 episodes per 100,000 person-years for invasive disease and 2.1 per 100,000 person-years for pneumonia. Behind those averages lay a stark mortality gradient: 14.9 percent of adults hospitalized with invasive pneumococcal disease died, compared with 3.0 percent of those admitted with pneumonia. The burden was consistently concentrated among people aged 65 and older, the group in which pneumococcal infection most often turns fatal.

The interrupted time series results told two very different stories. For invasive pneumococcal disease, neither the level nor the slope of incidence changed significantly after the childhood program began. The level ratio was 1.26 with a 95 percent confidence interval of 0.99 to 1.59, just shy of conventional significance, and the slope ratio of 0.97, with an interval of 0.93 to 1.01, offered no evidence of a declining trend. In plain terms, the feared invasive infections, which include bacteremia and meningitis, neither dropped as herd-effect optimists might have hoped nor surged in any statistically convincing way. The adult burden simply persisted.

Pneumonia told a more surprising tale. The level of pneumonia incidence in the post-vaccination period was significantly higher than before, with an incidence rate ratio of 1.92 and a confidence interval of 1.51 to 2.42, meaning the post-program level was nearly double the baseline. The slope, however, was statistically flat, at 1.02 with an interval of 1.00 to 1.04, indicating that rates were not climbing year over year but had shifted upward as a step. The economic dimension followed the same pattern: the average total direct cost per pneumonia episode rose from 3.1 million Korean Won before the program to 4.1 million Won after it, an increase that ripples through a national health system when multiplied across thousands of admissions.

Why would a vaccine that protects children appear to coincide with more adult pneumonia? The authors are careful to avoid overinterpreting the association, and they point to several plausible explanations. Increased surveillance and heightened diagnostic awareness, particularly around respiratory illness, may have driven more hospitalizations to be coded and counted as pneumonia in the later period, inflating apparent incidence without a true rise in disease. Changes in coding practice, an aging population and shifting healthcare-seeking behavior could all contribute. It is also worth noting that pneumonia is a clinically broad category: many pneumonias in adults are not caused by pneumococcus at all, so a vaccine targeting one bacterium would not be expected to reverse trends driven by viruses and other pathogens.

The stability of invasive pneumococcal disease is equally instructive. Indirect, or herd, protection from childhood conjugate vaccination has been documented in several high-income countries, where declines in vaccine-type invasive disease among adults followed pediatric immunization. But the magnitude of that effect depends on how much of adult carriage and disease is caused by the strains covered by the vaccine, on how quickly non-vaccine strains fill the vacated ecological niche, and on adult vaccination coverage with the older polysaccharide vaccine, PPSV23, which South Korea has also deployed in older adults. The new study cannot disentangle these forces, but its results suggest that in the South Korean setting, the indirect benefit to adults from PCV13 in children was not strong enough to bend the invasive disease curve within five years.

The study comes with strengths and caveats that readers should weigh. Its great advantage is scale: a population-based database spanning a full decade, capturing hospitalizations across the entire country rather than a sample of sentinel hospitals. Its limitations are those inherent to claims data. Case identification relied on diagnostic codes rather than bacterial culture or polymerase chain reaction confirmation, so some episodes coded as pneumonia may not have been pneumococcal, and some true pneumococcal pneumonias may have been missed. The study was funded by Merck Sharp & Dohme, a subsidiary of Merck & Co., with study activities contracted to IQVIA, and several authors are employees or paid consultants of those companies, relationships disclosed in the publication. The descriptive design also means the analysis shows temporal association, not causation.

For policymakers, the message is less a verdict on PCV13 than a reminder that childhood immunization is not a complete answer for adult respiratory disease. The authors conclude that the incidence of invasive pneumococcal disease in South Korean adults remained stable while the incidence and economic burden of pneumonia increased after the vaccine entered the childhood program, and that vaccine use alongside factors such as increased surveillance may explain the observed results. As newer, higher-valency conjugate vaccines reach adult immunization schedules worldwide, studies like this one underscore the need for direct adult vaccination strategies, robust surveillance that can distinguish pneumococcal from non-pneumococcal pneumonia, and continued economic evaluation of who bears the cost when prevention falls short. The decade of Korean data suggests that protecting the oldest adults may require protecting them directly.

Subject of Research: Impact of childhood PCV13 vaccination on hospitalized adult pneumococcal disease in South Korea

Article Title: Association between introduction of 13-valent pneumococcal conjugate vaccine and burden of hospitalized adult pneumococcal disease in South Korea – a population-based retrospective database study

Article References: Song, J. Y., Choi, E. H., Choe, Y. J., Yeo, S.-H., Patel, D., Lim, C. T. K., Lee, Y. E., Yamada, E., & Sukarom, I. (2026). Association between introduction of 13-valent pneumococcal conjugate vaccine and burden of hospitalized adult pneumococcal disease in South Korea – a population-based retrospective database study. BMC Public Health. https://doi.org/10.1186/s12889-026-29058-6

Image Credits: AI Generated

DOI: 10.1186/s12889-026-29058-6

Keywords: pneumococcal disease, PCV13, pneumonia, vaccination, herd immunity, South Korea, epidemiology, invasive pneumococcal disease, healthcare costs, public health, National Health Information Database, interrupted time series

The communities at the heart of the study are quilombola communities, settlements founded by Afro-Brazilian descendants of enslaved people, many of which retain distinct cultural identities and deep historical ties to their territories. Across Brazil, these communities face persistent barriers to accessing and using health services, including geographic isolation, socioeconomic disadvantage, and structural inequities that have proven resistant to broad national policies. The researchers argue that the first 1,000 days of life, spanning conception through a child’s second birthday, represent a critical window during which targeted, inexpensive interventions can yield lifelong benefits. Training the primary healthcare professionals who serve these communities on the legal and human rights of women and children, they hypothesized, offered a cost-effective and scalable strategy to improve outcomes precisely where the need is greatest.

To test that hypothesis rigorously, the team designed a quasi-experimental, controlled interrupted time-series study comparing two neighboring municipalities: Alcântara, which received the intervention, and Guimarães, which served as the control. Interrupted time-series designs are among the strongest observational methods available for evaluating policy and program effects, because they track outcomes over long stretches of time before and after an intervention, allowing researchers to distinguish genuine changes in trend from ordinary fluctuation. By including a control municipality, the researchers could further account for broader secular trends, such as national vaccination campaigns or economic shifts, that might otherwise be mistaken for effects of the training program.

The intervention itself was built around an educational program known within the broader EUQUERO project, whose full name, Engaging Users for Quality Enhancement and Rights: Strengthening the maternal and child healthcare system over the first 1000 days in Brazil, signals its dual emphasis on user engagement and rights. Rather than relying on passive lectures, the program employed active learning methods, an approach that requires participants to engage directly with material through discussion, problem-solving, and application to their daily practice. The content focused specifically on the rights of women and children in maternal and child healthcare, aiming to equip community health agents and other primary care professionals with both the knowledge and the confidence to act on those rights in their routine work.

For the evaluation, the researchers drew on monthly data from SISAB, Brazil’s national Health Information System for Primary Care, covering the period from 2014 to 2023. Ten maternal and child health indicators were analyzed, providing a decade-long window on service delivery in both municipalities. The statistical toolkit was correspondingly sophisticated: Prais-Winsten regression, which corrects for the autocorrelation that plagues time-series data, was used to estimate trends and level changes, while ARIMA and seasonal ARIMA models offered complementary estimates of the intervention’s impact. Model selection relied on standard diagnostic criteria including the Akaike and Bayesian Information Criteria, root mean square error, and autocorrelation tests at lag one, ensuring that the reported effects were not artifacts of poorly specified models.

The results, measured twelve months after the intervention, were striking. In Alcântara, antenatal visits carried out by community health agents rose dramatically, with a regression coefficient of 64.92 and a 95 percent confidence interval spanning 34.33 to 95.51, a result with a p-value below 0.001. Complementary breastfeeding also increased significantly, with a coefficient of 10.62 and a confidence interval of 5.01 to 16.23, again with p below 0.001. Full vaccination coverage in children under two climbed as well, with a coefficient of 30.33 and a confidence interval of 8.61 to 52.04, corresponding to a p-value of 0.006. These three indicators, spanning pregnancy care, infant nutrition, and immunization, represent core pillars of the first 1,000 days agenda, and their simultaneous improvement suggests the intervention touched multiple points along the continuum of maternal and child care.

The contrast with the control municipality sharpened the picture considerably. In Guimarães, all ten indicators declined over the same period, a pattern that makes the gains in Alcântara all the more remarkable and argues strongly that the training program, rather than some region-wide improvement, drove the changes. The interrupted time-series framework also captured a less flattering result: health education activities directed at pregnant women in Alcântara actually decreased, with a coefficient of negative 3.25 and a confidence interval of negative 5.94 to negative 0.56, p equal to 0.01. The authors report this decline transparently, and it serves as a reminder that even successful interventions can redistribute effort in unexpected ways, perhaps as trained workers shifted time toward direct antenatal visits and other hands-on services.

What makes the study especially compelling is the combination of methodological rigor and modest cost. The intervention involved no new clinics, no additional pharmaceutical supplies, and no large-scale infrastructure investment. It consisted of educating the people already embedded in the community, the community health agents who form the backbone of Brazil’s Family Health Strategy and who are often the only regular point of contact between the health system and remote or marginalized populations. If a relatively brief, rights-based training can shift indicators as consequential as vaccination coverage and breastfeeding by the margins observed here, the implications for health policy in Brazil and beyond are substantial. The approach is, as the authors emphasize, both cost-effective and scalable, qualities that matter enormously in resource-constrained settings.

The study also contributes to a growing body of evidence that health equity is not achieved through services alone but through the realization of rights. Quilombola populations, like many Indigenous and traditional communities in Brazil, hold specific legal entitlements to healthcare, yet those entitlements frequently go unrealized because frontline workers are unaware of them or lack the practical tools to act. By centering the training on rights rather than solely on clinical protocols, the EUQUERO program addressed a structural root of inequity: the gap between what the law promises and what the health system delivers. The measured improvements in Alcântara suggest that closing that gap, even partially, translates directly into more antenatal contact, better infant feeding practices, and more fully immunized children.

Caveats remain, as they do in any quasi-experimental study. The design compared a single intervention municipality with a single control, and while the decade of monthly data and the dual modeling strategy lend confidence to the findings, the generalizability to other quilombola territories and other countries will require replication. The observed decline in health education activities for pregnant women also warrants follow-up to understand whether it reflects beneficial reallocation of effort or a genuine service gap. Nevertheless, the study, funded by the United Kingdom’s Medical Research Council and the Maranhão research foundation FAPEMA, with additional support from Brazil’s CNPq and CAPES, stands as a rigorous demonstration that knowledge is an intervention in its own right. For the families of Alcântara, the first 1,000 days of life now look measurably better protected, and for policymakers searching for affordable levers against entrenched health inequity, the message is clear: train the workforce, teach the rights, and the indicators will follow.

Subject of Research: A rights-based professional training intervention to improve maternal and child health indicators in quilombola communities in Maranhão, Brazil

Article Title: Improving maternal and child healthcare through professional training in quilombola communities, Brazil: a controlled interrupted time-series study

Article References: de Sousa, F. S., Costa, E. M., Prado, I. A., Batista, R. F. L., Lamy, Z. C., Channon, A. A., & Thomaz, E. B. A. F. (2026). Improving maternal and child healthcare through professional training in quilombola communities, Brazil: a controlled interrupted time-series study. International Journal for Equity in Health. https://doi.org/10.1186/s12939-026-02996-8

Image Credits: AI Generated

DOI: 10.1186/s12939-026-02996-8

Keywords: maternal and child health, quilombola communities, Brazil, primary health care, community health agents, professional training, health equity, interrupted time series, vaccination coverage, breastfeeding, antenatal care, human rights

Sanming, a prefecture-level city in Fujian province, became famous in Chinese health-policy circles for a sequence of reforms that began in the early 2010s and progressively changed how doctors are paid, how hospitals earn revenue, and how money flows through the insurance system. The new analysis, led by Zhe Liu of Fudan University and Tongji Medical College with colleagues from Nankai University, Fudan’s School of Public Health, and Union Hospital, set out to measure whether those reforms actually moved care from hospitals back to primary care, and whether they changed the internal revenue composition of the institutions themselves. The answer, based on twelve years of monthly data, is a cautiously qualified yes.

The study’s engine is a statistical design known as interrupted time-series analysis, or ITSA. Rather than comparing Sanming to a matched control city, the researchers assembled 144 consecutive monthly observations spanning January 2013 to December 2024 and modelled the level and trend of each outcome before and after three policy interruptions: August 2015, January 2018, and October 2021. Each interruption corresponds to a distinct stage of Sanming’s reform programme, allowing the team to ask not simply whether things changed, but when they changed and in which direction. Segmented regression estimates a baseline trend, a level shift at each intervention point, and a change in slope afterwards, which together capture both immediate shocks and gradual drifts in behaviour.

The methodological care is notable. Only genuinely missing values were imputed using statistical modelling; observed zeros and statistically extreme values were deliberately retained rather than cleaned away, a choice that avoids silently erasing real-world events. Standard errors were computed with Newey-West corrections using a three-month lag to handle autocorrelation and heteroscedasticity, common afflictions of long monthly health series. The authors then stress-tested their findings across alternative lag orders, different transition windows around each intervention, and alternative seasonal specifications. Results were broadly stable across all of these checks, which matters because interrupted time-series findings can be fragile when the timing of a policy effect is uncertain or when seasonal illness cycles masquerade as policy signals.

The headline result concerns where people go for care. Mean monthly outpatient and emergency visits at primary care institutions rose from 160,018 in 2013 to 516,885 in 2024, more than a threefold increase, while the primary care share of all such visits climbed from 27.5 percent to 47.7 percent. In a system where hospitals had long absorbed the majority of routine encounters, nearly half of outpatient and emergency care now flowing through primary care represents a structural shift, not a statistical rounding error. The most striking inflection came after the August 2015 intervention: the monthly trend in total visits accelerated by 8,451 visits per month (95 percent confidence interval 4,773 to 12,129), the trend in primary care visits accelerated by 7,284 visits per month (95 percent CI 3,820 to 10,747), and the primary care visit-share trend rose by 0.442 percentage points per month (95 percent CI 0.245 to 0.640), all statistically significant at P less than 0.001.

The January 2018 stage tells a different and arguably more interesting story. After that interruption, the trends in inpatient admissions, total visits, provider-specific visits, the overall hospitalization rate, and the primary care visit share all declined. In other words, the second reform phase appears to have cooled an expansion that the first phase had ignited, tempering growth in hospital activity and even slowing the momentum of primary care uptake. This pattern is consistent with reforms that tightened accountability for admissions and discouraged unnecessary hospitalization, though the study’s design cannot assign the change to any single lever. What it does show is that payment architecture can bend utilization curves in both directions, which is precisely what a policy instrument should be able to do.

The October 2021 stage produced a further increase in the primary care visit-share trend, suggesting that later reforms continued to nudge the system toward community-based care. However, the inpatient findings from this later period were attenuated once the researchers adjusted for the COVID-19 pandemic, a reminder that the pandemic scrambled utilization patterns worldwide and that any before-and-after comparison touching 2020 through 2022 must contend with an unprecedented confounder. The authors are appropriately careful here: the pandemic adjustment softened some conclusions without overturning the core pattern of primary care gains.

Beyond utilization, the study examined how the money itself moved. The researchers tracked hospital and primary care medical revenue, and within each sector decomposed revenue into medical service revenue, pharmaceutical revenue, medical consumables, and examination and laboratory revenue. These shares are diagnostic gold in Chinese health policy because the old fee-for-service regime famously rewarded drug sales, high-tech tests, and consumables over the cognitive work of medicine. A shift in revenue composition away from pharmaceuticals and consumables toward medical services is the financial fingerprint of Sanming’s remuneration reforms, which tied physician pay to service value rather than drug margins. The study reports that successive reform stages were associated with changes in institutional revenue composition, indicating that the payment redesign did not merely redirect patients but also restructured what institutions earned money for.

The authors are explicit about the limits of causal inference in their design. A single-group interrupted time series without a comparison area cannot rule out secular trends, concurrent policies, or broader economic forces as alternative explanations. Their conclusion is deliberately measured: the temporal associations are consistent with, but do not demonstrate, a role for aligned payment accountability, remuneration arrangements, and primary care capacity. That honesty is refreshing in a field where reform success stories are often oversold, and it does not diminish the practical significance of the findings. Replicating Sanming’s trajectory elsewhere would require the same alignment of insurance payment rules, physician salary structures, and grassroots clinical capacity, and the study suggests that misalignment of any one component could blunt the effect.

For the international audience, Sanming’s experiment speaks to a universal question: can you redesign incentives to make primary care the default rather than the afterthought? The Sanming data suggest that when payment accountability, physician remuneration, and community capacity are pushed in the same direction, patient flows follow, with the primary care share of outpatient and emergency visits nearly doubling over the study period. The caveats, no control region, pandemic contamination of the later years, and the inherent ambiguity of before-and-after inference, are real. But the scale and persistence of the shift, documented month by month across twelve years with robust sensitivity analyses, make this one of the most compelling natural experiments in health-system reform to date. As countries from the United States to the United Kingdom wrestle with hospital overload and underfunded primary care, a mid-sized Chinese city has quietly produced a dataset worth studying in every health ministry on earth.

Subject of Research: Provider payment reform and primary care utilization in China's Sanming health reform

Article Title: Payment reform, remuneration incentives, and changes in service utilization and institutional revenue composition: an interrupted time-series analysis from Sanming, China

Article References: Liu, Z., Tang, F., Qin, X., Zheng, S., & Peng, J. (2026). Payment reform, remuneration incentives, and changes in service utilization and institutional revenue composition: an interrupted time-series analysis from Sanming, China. International Journal for Equity in Health. https://doi.org/10.1186/s12939-026-03032-5

Image Credits: AI Generated

DOI: 10.1186/s12939-026-03032-5

Keywords: payment reform, remuneration incentives, primary care, interrupted time series, Sanming, China, health policy, service utilization, hospital revenue, health equity, health economics, health system reform